Skip to main content

Table 3 Prognostic significance of selected genes in prostate cancer cohorts

From: Independence of HIF1a and androgen signaling pathways in prostate cancer

  Swedish Cambridge Long Taylor TCGA
TWIST1 2.05
(1.30–3.22)
P = 0.0019
0.95
(0.39–2.35)
P = 0.917
1.46
(0.84–2.54)
P = 0.178
2.69
(1.11–6.49)
P = 0.028
1.72
(1.13–2.60)
P = 0.01
KCNN2 2.39
(1.51–3.79)
P = 0.000216
1.91
(0.75–4.86)
P = 0.17
1.52
(0.87–2.27)
P = 0.14
1.78
(0.78–4.08)
P = 0.17
0.84
(0.56–1.26)
P = 0.41
SPRED1 NA 0.90
(0.36–2.23)
P = 0.81
0.76
(0.44–1.32)
P = 0.33
0.96
(0.43–2.13)
P = 0.91
0.96
(0.64–1.44)
P = 0.85
PPFIBP2 NA 1.21
(0.49–3.02)
P = 0.68
1.73
(0.99–3.03)
P = 0.05
0.86
(0.38–1.92)
P = 0.70
0.76
(0.50–1.13)
P = 0.17
JAG1 1.36
(0.88–2.10)
P = 0.17
2.23
(0.85–5.88)
P = 0.10
2.293
(1.28–4.12)
P = 0.005
1.25
(0.56–2.80)
P = 0.59
1.30
(0.87–1.94)
P = 0.21
IGFBP3 1.00
(0.65–1.55)
P = 0.99
1.09
(0.44–2.68)
P = 0.86
1.56
(0.89–2.73)
P = 0.12
1.99
(0.85–4.66)
P = 0.11
2.07
(1.36–3.20)
P = 0.0008
NDRG1 2.28
(1.43–3.64)
P = 0.0005
1.43
(0.58–3.56)
P = 0.44
0.81
(0.47–1.41)
P = 0.45
0.78
(0.34–1.75)
P = 0.54
0.96
(0.64–1.43)
P = 0.82
  1. BCR biochemical recurrence; OS overall survival; NA not applicable
  2. Values are hazard ratios (95% confidence intervals). Cohorts were stratified by the median expression of each gene